Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Study the Pharmacokinetic Characteristics of TQ-B3233 in the Human Body, Recommend a Reasonable Regimen for Subsequent Research

Trial Profile

To Study the Pharmacokinetic Characteristics of TQ-B3233 in the Human Body, Recommend a Reasonable Regimen for Subsequent Research

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs TQ-B3233 (Primary)
  • Indications Malignant melanoma; Tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 03 Jan 2019 Last check against ClinicalTrials.gov: US National Institutes of Health
    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top